1 Quigley, EM & Flourie, B (2007) Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 19, 166–172.
2 Spiller, P (2008) Review Article: probiotics and prebiotics in irritable bowel syndrome (IBS). Aliment Pharmacol Ther 28, 385–396.
3 Camilleri, M (2006) Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 40, 264–269.
4 Johansson, ML, Nobaek, S, Berggren, A, et al. (1998) Survival of Lactobacillus plantarum DSM 9843 (299v), and effect on the short-chain fatty acid content of faeces after ingestion of a rose-hip drink with fermented oats. Int J Food Microbiol 42, 29–38.
5 Larsen, CN, Nielsen, S, Kaestel, P, et al. (2006) Dose–response study of probiotic bacteria Bifidobacterium animalis subsp. lactis BB-12 and Lactobacillus paracasei subsp. paracasei CRL-341 in healthy young adults. Eur J Clin Nutr 60, 1284–1293.
6 Olivares, M, Diaz-Ropero, MA, Gomez, N, et al. (2006) Oral administration of two probiotic strains, Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711, enhances the intestinal function of healthy adults. Int J Food Microbiol 107, 104–111.
7 Yamano, T, Iino, H, Takada, M, et al. (2006) Improvement of the human intestinal flora by ingestion of the probiotic strain Lactobacillus johnsonii La1. Br J Nutr 95, 303–312.
8 Matsumoto, K, Takada, T, Shimizu, K, et al. (2006) The effects of a probiotic milk product containing Lactobacillus casei strain Shirota on the defecation frequency and the intestinal microflora of sub-optimal health state volunteers: a randomized placebo-controlled cross-over study. Biosci Microflora 25, 39–48.
9 Duez, H, Pelletier, C, Cools, S, et al. (2000) A colony immunoblotting method for quantitative detection of a Bifidobacterium animalis probiotic strain in human faeces. J Appl Microbiol 88, 1019–1027.
10 Pochart, P, Marteau, P, Bouhnik, Y, et al. (1992) Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion. Am J Clin Nutr 55, 78–80.
11 Berrada, N, Lemeland, JF, Laroche, G, et al. (1991) Bifidobacterium from fermented milks: survival during gastric transit. J Dairy Sci 74, 409–413.
12 Rochet, V, Rigottier-Gois, L, Ledaire, A, et al. (2008) Survival of Bifidobacterium animalis DN-173 010 in the faecal microbiota after administration in lyophilised form or in fermented product – a randomised study in healthy adults. J Mol Microbiol Biotechnol 14, 128–136.
13 Agrawal, A, Houghton, LA, Morris, J, et al. (2009) Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 29, 104–114.
14 Guyonnet, D, Chassany, O, Ducrotté, P, et al. (2007) Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 26, 475–486.
15 Marteau, P, Cuillerier, E, Méance, S, et al. (2002) Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 16, 587–593.
16 Méance, S, Cayuela, C, Raimondi, A, et al. (2003) Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Microb Ecol Health Dis 15, 15–22.
17 Méance, S, Cayuela, C, Turchet, P, et al. (2001) A fermented milk with a Bifidobacterium probiotic strain DN-173 010 shortened oro-faecal gut transit time in elderly. Microb Ecol Health Dis 13, 217–222.
18 Guyatt, GH, Deyo, RA, Charlson, M, et al. (1989) Responsiveness and validity in health status measurement: a clarification. J Clin Epidemiol 42, 403–408.
19 Irvine, EJ, Whitehead, WE, Chey, WD, et al. (2006) Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 130, 1538–1551.
20 Heaton, KW, O'Donnell, LJ, Braddon, FE, et al. (1992) Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology 102, 1962–1967.
21 Guyonnet, D, Chassany, O, Picard, C, et al. (2008) Perceived subject outcomes and impact on health-related quality of life associated with diet using the new Food Benefits Assessment (FBA©) questionnaire: development and psychometric validation. Public Health Nutr 11, 1163–1172.
22 Dupuy, HJ (1984) . In Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies, , pp. 170–184 [Wenger, NK, Mattson, ME, Furberg, CF and Elinson, J, editors]. New York: Le Jacq Publishing.
23 Walters, SJ & Brazier, JE (2005) Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 14, 1523–1532.
24 Juniper, EF, Guyatt, GH, Willan, A, et al. (1994) Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 47, 81–87.
25 European Medicines Agency (1998) ICH Topic E 9. Statistical Principles for Clinical Trials. . London: EMEA.
26 Goetze, O, Fruehauf, H, Pohl, D, et al. (2008) Effect of a prebiotic mixture on intestinal comfort and general wellbeing in health. Br J Nut 100, 1077–1085.
27 Hernando-Harder, AC, von Bunau, R, Nadarajah, M, et al. (2008) Influence of E. coli strain Nissle 1917 (EcN) on intestinal gas dynamics and abdominal sensation. Dig Dis Sci 53, 443–450.
28 McFarland, LV & Dublin, S (2008) Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14, 2650–2661.
29 Cummings, JH, Antoine, JM, Azpiroz, F, et al. (2004) PASSCLAIM – gut health and immunity. Eur J Nutr 43, Suppl. 2, II118–II173.
30 van Kerkhoven, LA, Eikendal, T, Laheij, RJ, et al. (2008) Gastrointestinal symptoms are still common in a general Western population. Neth J Med 66, 18–22.
31 Moayyedi, P, Ford, AC, Talley, NJ, et al. (2008) The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut .
32 Nuovo, J, Melnikow, J & Chang, D (2002) Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA 287, 2813–2814.
33 Altman, DG, Schulz, KF, Moher, D, et al. (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134, 663–694.
34 Bouglé, D, Roland, N, Lebeurrier, F, et al. (1999) Effect of propionibacteria supplementation on fecal bifidobacteria and segmental colonic transit time in healthy human subjects. Scand J Gastroenterol 34, 144–148.
35 Kim, HJ, Camilleri, M, McKinzie, S, et al. (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17, 895–904.
36 Sairanen, U, Piirainen, L, Grasten, S, et al. (2007) The effect of probiotic fermented milk and inulin on the functions and microecology of the intestine. J Dairy Res 74, 367–373.
37 Bartram, HP, Scheppach, W, Gerlach, S, et al. (1994) Does yogurt enriched with Bifidobacterium longum affect colonic microbiology and fecal metabolites in healthy subjects? Am J Clin Nutr 59, 428–432.
38 Collado, MC, Moreno, Y, Cobo, JM, et al. (2006) Molecular detection of Bifidobacterium animalis DN-173010 in human feces during fermented milk administration. Food Res Int 39, 530–535.
39 Parkes, GC, Brostoff, J, Whelan, K, et al. (2008) Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 103, 1557–1567.